FOR IMMEDIATE RELEASE

AMNEAL ANNOUNCES THREE NEW GENERIC LIQUIDS

Risperidone, Ondansetron and Levetiracetam oral solutions further expand generic maker’s portfolio

Bridgewater, NJ (USA), July 11, 2011 – Amneal Pharmaceuticals, LLC is pleased to introduce three new generic drugs in liquid form:

- Risperidone oral solution
- Ondansetron oral solution
- Levetiracetam oral solution

Risperidone oral solution is available in 1 mg/mL (5 mg/5 mL) strength. Amneal’s generic is an AA-rated, therapeutically equivalent alternative to Risperdal® (a registered trademark of Ortho-McNeil-Janssen, a unit of Johnson & Johnson Corporation). The clear, unflavored liquid comes in a 1 oz/30 mL bottle packaged with a calibrated pipette. Risperidone is an antipsychotic agent indicated for treatment of schizophrenia, bipolar disorder and autism.

Ondansetron oral solution is available in 4 mg/5 mL strength. Amneal’s generic is an AA-rated, therapeutically equivalent alternative to Zofran® (a registered trademark of GlaxoSmithKline plc). The clear, strawberry-scented liquid is sold in a 1.7 oz/50 mL bottle. Ondansetron is an antiemetic indicated for prevention of nausea and vomiting associated with cancer treatment and postoperative recovery.

Levetiracetam oral solution is available in 100 mg/mL strength. The Amneal generic is an AA-rated, therapeutically equivalent alternative to Keppra® (a registered trademark of UCB Pharma, S.A. Corporation). The clear, grape-flavored liquid is packaged in a new smaller 4 oz/118 mL bottle as well as the standard 16 oz/473 mL size. Levetiracetam is an antiepileptic indicated for treatment of epileptic seizures.

"Since Amneal’s acquisition of its Branchburg, New Jersey liquids plant a few years ago, we have committed significant R&D resources to developing a powerful product pipeline in the liquid, nasal spray and topical dosage forms that are now beginning to come to market,” says Chirag Patel, Amneal’s president. “And the most exciting products are still to come, enhancing an already strong pipeline.”

All three Amneal products are now shipping and available through wholesalers-distributors as well as directly to the trade. The Branchburg facility, one of the company’s five fully cGMP-compliant production plants in the U.S., manufactures liquids, nasal sprays, topicals and semisolids.

Risperidone, Ondansetron and Levetiracetam oral solutions are the latest additions to Amneal’s diverse portfolio of high quality generic drugs in the company’s on-line catalog at www.amneal.com. The comprehensive web catalog is designed for easy customer and
patient access to essential information, images and literature such as product outserts, prescribing information, labels, patient medication guides, material safety data sheets (MSDS) and high-resolution product photos.

Please see information on risks, side effects, precautions and contraindications of these products, including the boxed warning for Risperidone, in the full prescribing information at www.amneal.com/products.

Amneal Pharmaceuticals, LLC, with principal offices in Bridgewater, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as “Generic’s New Generation,” the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal’s aggressive growth strategy, as is the company’s strong commitment to deep customer relationships and maximum value creation. Amneal delivers high quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.

###

CONTACT:

Jim Luce  
Executive Vice President, Sales & Marketing  
Amneal Pharmaceuticals, LLC  
Direct: 949-610-8018  
Fax: 949-610-8218  
E-mail: jim@amneal.com  
www.amneal.com  
620 Newport Center Drive, 14th Floor  
Newport Beach, California 92660